These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1819 related articles for article (PubMed ID: 28263132)

  • 1. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
    Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal Therapy.
    Son CH; Hamstra DA; Feng FY; Liauw SL
    Am J Clin Oncol; 2017 Aug; 40(4):348-352. PubMed ID: 25436827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?
    Soyano T; Kozuka T; Kashihara K; Murakami Y; Yonese J; Sasamura K; Shimoyachi N; Kashihara T; Yoshioka Y; Oguchi M
    Jpn J Clin Oncol; 2023 Jun; 53(6):514-521. PubMed ID: 36946312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
    Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
    Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
    Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
    Saad A; Goldstein J; Lawrence YR; Spieler B; Leibowitz-Amit R; Berger R; Davidson T; Urban D; Tsang L; Alezra D; Weiss I; Symon Z
    Radiat Oncol; 2017 Jan; 12(1):5. PubMed ID: 28061904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
    Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
    Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.